Compare Amplify Cybersecurity ETF (HACK) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Cybersecurity ETF vs Merck & Co., Inc. — how do they compare? Amplify Cybersecurity ETF trades at $118.43, while Merck & Co., Inc. trades at $130.78 (market cap $323.00B). The key difference: Merck & Co., Inc. pays a 2.6% dividend while Amplify Cybersecurity ETF pays none. Which is the better fit depends on your goals.
| HACK | MRK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $119.19 | $131.84 |
52-Week Low | $70.69 | $77.60 |
Market Cap | — | $323.00B |
Enterprise Value | — | $369.77B |
Dividend Yield | — | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HACK is trading at $115.42, up 1.97% with strong bullish momentum from moving averages. The ETF recently hit a 52-week high and is positioned to benefit from escalating cybersecurity spending, which is forecast to exceed $300 billion in 2026. Technical indicators show the stock is near resistance at $116 with RSI suggesting mild overbought conditions. Institutional interest is growing, with D.A. Davidson increasing its position by 44.8% in Q1 2026.
The outlook remains positive as AI-driven cyber threats fuel demand for cybersecurity solutions. Key risks include market volatility and competitive pressures from other cybersecurity ETFs. Analyst sentiment is bullish with the ETF capturing the full cybersecurity stack as enterprises increase digital defense budgets amid rising AI-powered threats.
Merck & Co. (MRK) trades at $130.51, up 1.51% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $139.90. Recent earnings beats in Q4 2025 and Q1-Q2 2026 highlight operational strength, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock shows robust cash flow from operations of $16.47B in 2025, though a high P/E ratio of 104.74 signals premium valuation.
The outlook for MRK is positive, driven by strategic M&A and earnings momentum, but risks include patent expirations and regulatory pressures. Investors may find opportunity in its dividend yield and growth initiatives, yet should weigh elevated valuation against potential headwinds from competitive and macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amplify Cybersecurity ETF
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
